RxDoctor Payments Data

Patricia Martino, NP

Adult Health · Warwick, RINPI 1689699175

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 37.9% of the total.

$494in general payments, 2019–2025

Across 20 payments — averaging $24.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$187
  • Boehringer Ingelheim$80
  • GSK$59
  • Edwards Lifesciences$46
  • Exact Sciences$32
  • Lundbeck LLC$27
  • plus $63 from 3 others

What the payments were for

  • Food & beverage$494100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$494 in reported general payments places this provider in the 65th percentile of 65 adult health providers in Rhode Island.

See all adult health providers in Rhode Island

Medicare billing

Part B allowed, 2024
$20,167
Medicare patients
144
Services billed
436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$26,524
JardianceEmpagliflozin16$9,454
Omeprazole102$1,946
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,290
Atorvastatin Calcium109$1,196
Levothyroxine Sodium107$890
SynthroidLevothyroxine Sodium11$887
Rosuvastatin Calcium61$858
Lisinopril90$848
Albuterol Sulfate HfaAlbuterol Sulfate38$828
Famotidine39$691
Gabapentin57$674
Fluticasone Propionate29$629
Amlodipine Besylate78$597
Trazodone Hcl34$426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$59$26,52440 claims
Boehringer IngelheimJardiance$80$9,45416 claims
AbbVieSynthroid$187$88711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 65 adult health providers in Rhode Island.

Other adult health in Warwick

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →